How are energy investors positioned?
IRVING, Texas - Biote Corp. (NASDAQ: BTMD), a company specializing in personalized hormone optimization and therapeutic wellness, has announced the appointment of Rich Barrera to its Board of Directors, effective immediately. The company, which currently trades at $3.93 and boasts a market capitalization of $188 million, has demonstrated strong financial health with a 71% gross profit margin and positive earnings of $0.60 per share over the last twelve months. According to InvestingPro analysis, the stock appears fairly valued based on its current Fair Value assessment. The addition of Barrera, the Founder and CEO of Roystone Capital, is expected to strengthen Biote’s strategic planning and growth initiatives.
Rich Barrera’s extensive experience in investment management spans over two decades. Prior to his current role at Roystone Capital, Barrera co-managed portfolios at Redwood Capital Management and Glenview Capital Management. His educational background includes an MBA from Harvard Business School and a BS in Accounting and Finance from the Wharton School. His appointment comes as Biote demonstrates solid financial metrics, with InvestingPro data showing a notable 8.2% stock price increase over the past week and an impressive free cash flow yield.
Marc Beer, Executive Chairman of Biote, expressed confidence in Barrera’s alignment with the company’s long-term value creation strategy. Beer highlighted Barrera’s investment acumen and prior collaboration with Biote through Roystone Capital, which is one of the company’s top institutional shareholders.
Biote has positioned itself as a pioneer in the field of healthy aging, focusing on training medical providers to address early indicators of aging-related conditions. The company’s approach aims to provide accessible symptom relief for patients and support the success of practitioners’ clinics.
As Biote continues to navigate the competitive landscape of the wellness industry, the expertise of its newly elected board member is anticipated to contribute to the execution of its growth plan. This strategic move comes as the company endeavors to expand its market presence and enhance shareholder value. The company’s financial outlook appears promising, with analysts expecting net income growth this year. Discover more detailed insights and analysis about Biote’s performance through InvestingPro, which offers comprehensive research reports and additional ProTips for informed investment decisions.
This announcement is based on a press release statement from Biote Corp. and is intended to provide factual information regarding the company’s board election and its potential implications for the company’s future direction.
In other recent news, Biote Corp announced its Q1 2025 earnings, which exceeded Wall Street expectations. The company reported an earnings per share (EPS) of $0.37, significantly higher than the projected $0.14, and revenue of $49 million, surpassing the anticipated $47.2 million. This performance was driven by a 25.5% increase in dietary supplement sales, contributing to a 4.7% overall revenue growth from the previous year. Additionally, Biote Corp’s gross profit margin improved by 300 basis points to 74.3%. The company has also projected a revenue guidance range of $202 million to $208 million for 2025, with an expected adjusted EBITDA between $59 million and $64 million. In another development, Steven J. Heyer resigned from Biote Corp’s board of directors, effective immediately, with no disagreements cited regarding company operations or policies. The board has not yet appointed a successor to fill the vacancy. These developments reflect Biote Corp’s ongoing efforts to strengthen its market position and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.